Acyclic Cucurbit[n]uril-Type Molecular Containers Bind Neuromuscular Blocking Agents In Vitro and Reverse Neuromuscular Block In Vivo
Acyclic Cucurbit[n]uril-Type Molecular Containers Bind Neuromuscular Blocking Agents In Vitro and Reverse Neuromuscular Block In Vivo
复制标题
DOI:
10.1002/anie.201206031
复制
发表时间:
2012-01-01
影响因子:
16.6
通讯作者:
Isaacs, Lyle
中科院分区:
文献类型:
--
作者:
Ma, Da;Zhang, Ben;Isaacs, Lyle
Annually, more than 400 million patients receive curare-type neuromuscular blocking agents (NMBAs) during anesthesia in operating rooms, intensive care units, and emergency medicine departments. NMBAs that are widely used in the clinical practice of anesthesia include rocuronium, pancuronium, vecuronium, atracurium, and cisatracurium.[1] To speed up the recovery of the patient s muscle function and to prevent residual neuromuscular block, it is often necessary to reverse the biological effect of NMBAs at the end of the surgery.[2] Conventional reversal agents, such as neostigmine and edrophonium, exert their activity by increasing the levels of acetylcholine at the neuromuscular junction by competitive inhibition of acetylcholine esterase.[3] Unfortunately, these conventional reversal agents may cause cardiovascular side effects owing to their nonselective potentiation of muscarinic acetylcholine receptors and may even induce a (depolarizing) neuromuscular block in clinical practice when given in the absence of a NMBA.[4] A major advance in clinical anesthesia was made by the introduction of a g-cyclodextrin-derived molecular container known as Sugammadex (3, marketed as Bridion by Merck with sales of more than $100 million in 2010; Scheme 1), which binds rocuronium with high affinity (Ka= 1.05 107 mÀ1) in water and reverses the effects of rocuronium and vecuronium in vivo.[5] Sugammadex reverses neuromuscular block by sequestering rocuronium and vecuronium in the bloodstream, thereby depleting their concentration at the neuromuscular junction.[6] The sugammadex· rocuronium complexes are subsequently excreted in the urine. Sugammadex has had a major impact on the clinical practice of anesthesia in Europe but is not yet approved for use in the United States because of potential allergic reactions and hemorrhagic side effects.[7] As a result, there is a real need to develop alternative classes of molecular containers that function as reversal agents for the full range of clinically important NMBAs.We, and others, have been studying the synthesis and supramolecular chemistry of a new family of molecular containers known as cucurbit [n] urils (CB [n]), which comprise n glycoluril rings linked by 2n CH2 bridges.[8] The defining structural features of CB [n] molecular containers are a hydrophobic cavity guarded by two symmetry-equivalent electrostatically negative ureidyl C= O portals. Remarkably, CB [n] compounds display unusually high affinity (Ka routinely exceeds 109 mÀ1) toward alkane (di) ammonium ions in water.[9] Accordingly, CB [n] compounds have been used in a variety of applications including stimuli-responsive molecular machines, sensing ensembles, biomimetic processes, supramolecular polymers, and (targeted) drug delivery.[10] Given the high Ka values typically observed for CB [n]· guest